^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

    Excerpt:
    ...- Histopathological or ctDNA analysis positive for BRAF V600E mutant...
    Trial ID:
    VIC-BRAFMT-mCRC
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

    Excerpt:
    ...BRAFV600...
    Trial ID:
    NCT02164916
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A prospective, single-arm, open-label exploratory clinical study evaluating the efficacy and safety of the combination therapy of toramatinib, vemurafenib and cetuximab in the first-line treatment of unresectable or advanced BRAF V600E mutant colorectal cancer

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500105081
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

    Excerpt:
    ...- Cancers with positive BRAF V600 mutation detected by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory...
    Trial ID:
    NCT01787500
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

    Excerpt:
    ...- Patients with BRAV V600E mutation/KRAS WT based on the NGS or ARMS-PCR detection of tumor tissue;...
    Trial ID:
    NCT03727763
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    N Engl J Med
    Title:

    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Excerpt:
    …partial or complete response and tumor regression (Table 2 and Fig. 2 and ​and3, and Table S3 and Fig. S2 and S3 in the Supplementary Appendix), and prolonged disease stabilization (Fig. S4 in the Supplementary Appendix) were observed in several tumor types, including non–small-cell lung cancer (8 partial responses in the cohort of 20 patients), Erdheim–Chester disease or Langerhans’-cell histiocytosis (1 complete and 5 partial responses in the cohort of 18 patients), anaplastic thyroid cancer (1 complete and 1 partial response in the cohort of 7 patients), cholangiocarcinoma (1 partial response in the cohort of 8 patients), with anecdotal responses in patients with salivary-duct cancer, clear-cell sarcoma, low-grade serous ovarian cancer, glioblastoma, anaplastic ependymoma, pancreatic cancer, and carcinoma of unknown primary type (supplimentary info).
    DOI:
    10.1056/NEJMoa1502309
    Trial ID:
    NCT01524978
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

    Excerpt:
    Vemurafenib, in combination with irinotecan and cetuximab, was well tolerated in patients with refractory, BRAF-mutated metastatic colorectal cancer, and both survival outcomes and response rates exceeded prior reports for vemurafenib and for irinotecan plus cetuximab in BRAFV600E metastatic colorectal cancer.
    Secondary therapy:
    irinotecan
    DOI:
    10.1158/2159-8290.CD-16-0050
    Trial ID:
    NCT01787500